| Drug Name |
Axitinib |
| Drug ID |
BADD_D00193 |
| Description |
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).[L6676] Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative.[A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations. |
| Indications and Usage |
Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01EK01 |
| DrugBank ID |
DB06626
|
| KEGG ID |
D03218
|
| MeSH ID |
D000077784
|
| PubChem ID |
6450551
|
| TTD Drug ID |
D01ZRI
|
| NDC Product Code |
0069-0145; 54893-0032; 68554-0088; 63539-026; 82920-028; 0069-0151; 65344-0033; 63539-044; 54893-0043 |
| UNII |
C9LVQ0YUXG
|
| Synonyms |
Axitinib | AG 013736 | AG013736 | AG-013736 | Inlyta |
